Option Exercise Notice. Novartis will exercise an Option, if at all, by properly delivering a completed Option Exercise Notice in respect of such Option to Surface at any time during the applicable Option Exercise Period for such Option. For clarity, Novartis will be entitled to exercise a maximum of three (3) Options, and thereafter all rights and obligations with respect to any remaining Option Target will terminate in accordance with Section 4.2.7.
Option Exercise Notice. The term “
Option Exercise Notice. If GSK intends to exercise its Exclusive Option, GSK shall send within the Option Period a written notice to CureVac exercising such Exclusive Option (“Option Exercise Notice”). Following receipt of the Option Exercise Notice by CureVac, the Parties shall as soon as reasonably practicable agree a COVID R&D Plan and/or Commercialization plan, as applicable, for the further Development, Manufacture and Commercialization of the First-Gen COVID Vaccine Products.
Option Exercise Notice. The written notice from Option Holder received by the Administrative Agent during the Option Period confirming Option Holder's exercise of the Option granted under this Contract.
Option Exercise Notice. District acknowledges and agrees that upon Redevelopment Completion (i) all of the terms of Section 3.2 of the Option Agreement following the Optionee certification that is to accompany an Option Notice in clause (i) thereunder shall be deleted in their entirety and be of no further force or effect, and (ii) if LAFC is the Optionee following a USC Termination Event, then Optionee’s certification under Section 3.2 of the Option Agreement, as modified by clause (i) above, will be made by LAFC in reference to the LAFC Lease and not the USC Lease.
Option Exercise Notice. If GSK intends to exercise its Exclusive Option, GSK shall send (at any time before the expiry of the Option Period) a written notice to CureVac identifying the Optioned Product that GSK seeks to Develop ("Option Request"). Within [*****] following receipt of the Option Request, the Antigen/Antibody List Rep will perform an LNP clearance in accordance with Section 3.4. Within [*****] following the request, the Parties will hold a JSC meeting for discussing the details of the envisaged collaboration, and CureVac will notify GSK of the amount of the Option Exercise Fee and will provide to GSK all data, documents and information reasonably required by GSK to assess whether it wishes to exercise its Exclusive Option with respect to the respective Optioned Product. GSK shall exercise its Exclusive Option by sending written notice to CureVac within [*****] following such JSC meeting ("Option Exercise Notice"). Following receipt of the Option Exercise Notice by CureVac, the Parties shall as soon as reasonably practicable work on an initial R&D Plan for the Optioned Product in accordance with Section 4.3.2, and CureVac shall secure the LNP License from the LNP Provider, or in case GSK exercises its option, from the Option LNP Provider.
Option Exercise Notice. 11/14/2017 (by electronic mail and first-class post) 54 Sound Studio 0000 Xxxx Xxxx Xxxx Xxxx Xxxxxxxx, XX 00000 Xxxxxxxxx Associates, P.C. 0000 Xxxxxx xx xxx Xxxxxxxx, 00xx Xxxxx Xxx Xxxx, XX 00000 Attention: Xxxx Xxxxxxxxx, Esq. Dear Xx. Xxxxxx, Reference is made to that certain Amended and Restated Option Agreement (the “Agreement”) made the 13th day of November, 2017, by and among Royalty Exchange Inc., F.B.T. Productions LLC (“FBT”) and Em2M LLC (“Em2M”). Section references and capitalized terms herein have such meanings as in the Agreement. Pursuant to and in satisfaction of Section 5(a), we are pleased to formally provide notice that we are exercising the 25% Option. We have attached the current draft Proposed Agreement pursuant to Section 5(b), and look forward to promptly finalizing the agreement and closing on the Acquired Interest. We would suggest a call today or tomorrow to finalize the Proposed Agreement and schedule closing. Best regards, /s/ Xxxx Xxxxxxxxx Encl: Proposed Agreement cc: X. Xxxxxxxxx; X. Xxxxxxxx; X. XxXxxxxxx Exhibit 3: Form of Sellers Closing Certificate [Closing Date] Reference is made to that certain Purchase Agreement (the “Agreement”) made the [●] day of November, 2017, by and among Royalty Exchange Inc. and F.B.T. Productions LLC (“FBT”) and Em2M LLC (“Em2M”) (each, a “Seller” and, collectively, “Sellers”). Section references in this certificate refer to the Agreement. In connection with the Closing (as defined in the Agreement) and pursuant to and in satisfaction of Section 2(e)(ii), Sellers hereby confirm (a) the representations and warrantees in Section 3 are true and correct as of the date hereof (unless such representations and warrantees specifically relate to a prior date, in which case they are true and correct as of such date) and (b) Sellers remain in compliance with their covenants in Section 4 as of the date hereof. Kind regards,
Option Exercise Notice. If Licensee elects, in its sole discretion, to exercise the Option with respect to the Additional Invention, Licensee shall give written notice (the "Option Exercise Notice") to BURF of its election to exercise within 90 days after receipt of the Additional Invention Notice.
Option Exercise Notice. The Option shall be exercisable at any time and on any one or more occasions (up to an aggregate number of Shares equal to the number of Option Shares) by written notice given by the Placing Agent to the Company no later than the Option Expiry Time.
Option Exercise Notice. Within [***] after (i) the Parties have agreed on a Product Agreement for the applicable Option Product or (ii) the arbitrator has given a final decision in Baseball Arbitration, as applicable, BioNTech may notify Autolus in writing that it wishes to execute the applicable Product Agreement (a “Product Option Exercise Notice”). If BioNTech provides such a Product Option Exercise Notice, then the Parties shall execute such Product Agreement within [***] after Autolus’s receipt of the Product Option Exercise Notice. (b)
